An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
TipRanks on MSN
Sino Biopharm advances first-in-class ROCK2 inhibitor TDI01 into global first phase III IPF trial
Sino Biopharmaceutical ( ($HK:1177) ) just unveiled an update. Sino Biopharmaceutical has announced completion of enrollment of the first patient ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback